The overexpression of NRF2 could also increase the risk of cytarabine resistance in a ROS-independent manner by inhibiting MutS Homolog 2 (MSH2) expression in acute myeloid leukemia (AML) [72]. This evidence concerns the gene NFE2L2 and acute myeloid leukemia.